 |
English
|
正體中文
|
简体中文
|
Post-Print筆數 : 27 |
Items with full text/Total items : 109952/140887 (78%)
Visitors : 46320504
Online Users : 1012
|
|
|
Loading...
|
Please use this identifier to cite or link to this item:
https://nccur.lib.nccu.edu.tw/handle/140.119/71195
|
| Title: | The effects of omega-3 fatty acids monotherapy in Alzheimer s disease and mild cognitive impairment: A preliminary randomized double-blind placebo-controlled study |
| Authors: | Chiu,Chih-Chiang;Su,Kuan-Pin;Cheng,Tsung-Chi;Liu,Hsing-Cheng;Chang,Ching-Jui;Dewey,Michael E;Stewart,Robert;Huang,Shih-Yi |
| Contributors: | 統計系 |
| Date: | 2008.05 |
| Issue Date: | 2014-11-06 18:22:45 (UTC+8) |
| Abstract: | A 24-week, randomized, double-blind placebo-controlled study was carried out to test the feasibility of using omega-3 polyunsaturated fatty acids (PUFAs) monotherapy in people with cognitive impairment and to explore its effects on cognitive function and general clinical condition in these participants. Twenty three participants with mild or moderate Alzheimer’s disease and twenty three with mild cognitive impairment were randomized to receive omega-3 PUFAs 1.8 g/day or placebo (olive oil). The data of 35 (76%) participants with at least one post-treatment visit was analyzed. There were no severe adverse effects in either group and it suggests that omega-3 PUFAs were well tolerable in this population. The treatment group showed better improvement on the Clinician’s Interview-Based Impression of Change Scale (CIBIC-plus) than those in the placebo group over the 24 week follow-up (p = 0.008). There was no significant difference in the cognitive portion of the Alzheimer’s Disease Assessment Scale (ADAS-cog) change during follow-up in these two groups. However, the omega-3 fatty acids group showed significant improvement in ADAS-cog compared to the placebo group in participants with mild cognitive impairment (p = 0.03), which was not observed in those with Alzheimer’s disease. Higher proportions of eicosapentaenoic acid on RBC membranes were also associated with better cognitive outcome (p = 0.003). Further studies should be considered with a larger-sample size, diet registration, higher dosages, comparisons between different combinations of PUFAs, and greater homogeneity of participants, especially those with mild Alzheimer’s disease and mild cognitive impairment. |
| Relation: | Progress in Neuro-Psychopharmacology & Biological Psychiatr32(6),1538-1544 |
| Data Type: | article |
| DOI 連結: | http://dx.doi.org/http://dx.doi.org/10.1016/j.pnpbp.2008.05.015 |
| DOI: | 10.1016/j.pnpbp.2008.05.015 |
| Appears in Collections: | [統計學系] 期刊論文
|
Files in This Item:
| File |
Description |
Size | Format | |
|---|
| 1538-1544.pdf | | 449Kb | Adobe PDF2 | 730 | View/Open |
|
All items in 政大典藏 are protected by copyright, with all rights reserved.
|
著作權政策宣告 Copyright Announcement1.本網站之數位內容為國立政治大學所收錄之機構典藏，無償提供學術研究與公眾教育等公益性使用，惟仍請適度，合理使用本網站之內容，以尊重著作權人之權益。商業上之利用，則請先取得著作權人之授權。
The digital content of this website is part of National Chengchi University Institutional Repository. It provides free access to academic research and public education for non-commercial use. Please utilize it in a proper and reasonable manner and respect the rights of copyright owners. For commercial use, please obtain authorization from the copyright owner in advance.
2.本網站之製作，已盡力防止侵害著作權人之權益，如仍發現本網站之數位內容有侵害著作權人權益情事者，請權利人通知本網站維護人員(
nccur@nccu.edu.tw)，維護人員將立即採取移除該數位著作等補救措施。
NCCU Institutional Repository is made to protect the interests of copyright owners. If you believe that any material on the website infringes copyright, please contact our staff(
nccur@nccu.edu.tw). We will remove the work from the repository and investigate your claim.
